



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kristof Van Emelen

Serial No. : 10/507159 Art Unit: 1632

Filed : March 11, 2003 Examiner:

For : SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF

HISTONE DEACETYLASE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. \$1.56 and in accordance with 37 C.F.R. \$\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. \$1.56(b):

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☐ In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application

(other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with \( \square \) the first or Second After Final Submission, therefore: Statement in Accordance with \$1.97(e) (attached); or П Please charge Deposit Account No. 10the fee of \$180.00 as set forth in \$1.17(p). In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: П Statement in Accordance with \$1.97(e) (attached); or Please charge Deposit Account No. 10-П 0750/ USNP/ the fee of \$180.00 as set

forth in §1.17(p).

☐ In acc	ordance with §1.97(d), this Information
Disclosure State	ment is being filed after the mailing date of
either a Final A	ction under \$1.113 or a Notice of Allowance
under §1.311 but	before the payment of the Issue Fee.
Applicant(s) her	eby petition(s) for consideration of this
Information Disc	losure Statement. Included are: Statement in
Accordance with	\$1.97(e) as set forth below and the fee of
\$180.00 as set f	orth in \$1.17(p).
	of each of the references listed on the 0-1449 are enclosed herewith.
	s of only foreign patent documents and non- e are enclosed in accordance with 37 CFR 1.98
	of references listed on the attached Form PTO- d herewith EXCEPT THAT:
. t	in view of the voluminous nature of references (list as appropriate), and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
 6 .e	f any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Docket No. PRD-2010USPCT Application No: 10/507159

There are no listed	references which are not in the
English language.	
☐ The relevance of the not in the English language is	ose listed references which are as follows:
	of search report(s) from on(s), which are listed on the 9 609 D.
☐ Attached are the folpatent applications which may listed on the attached Submiss .	· ·
	ency or credit any overpayment to D-2010USPCT/AGK. This form is
	Respectfully submitted,
	/Alana G. Kriegsman/
•	Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants
Johnson & Johnson One Johnson & Johnson Plaza	

New Brunswick, NJ 08933-7003

(732) 524-1495 DATED: October 5, 2006 OCT 10 2006

PTO/SB/08A (08-00)
Approved for use through 1/03/12/02/1
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ed to respond to a collection of information unless it displays a valid OWB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

tute for form 1449A/PTO

(use as many sheets as necessary) Sheet 1of 2

Application Number	10/507159
Filing Date	03/11/2003
First Named Inventor	Kristof Van Emelen
Group Art Unit	1621
Examiner Name	
Attorney Docket Number	PRD-2010 USPCT

					U.S. PATENT DOCUMENTS		
		U.S. Petent Document					
Exeminer Initials	Cite No. <sup>1</sup>	Number	Kind C	Code <sup>2</sup> nown)	Name of Petentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Peges, Columns, Lines, where relevent passages o relevant figures appear
							00
						1	

#### FOREIGN PATENT DOCUMENTS

	Foreign Patent Document		ent	Name of Detector or	Date of Publication of Cited Document	Pages, Columns, Lines,	
Cite No.1	Cffice <sup>3</sup>	Number <sup>4</sup> K	indCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	₽°
	EP	0827742	A1	Vrie Universiteit Brussel	03-11-1998		
	wo	98/55449	A1 .	The University of Queensland & The Queensland Instituted of Medical Research	12-10-1998		
	wo	01/38322	A1	Methylgene, Inc.	05-31-2001		
	wo	01/70675	A2	Methylgene, Inc.	09-27-2001		
	_	-					
	No.1	Cite No.1 Cffice³ EP WO WO	Citie   Number   K	Citica* Number* KindCode* EP 0927742 A1  WO 98/55449 A1  WO 01/58322 A1	Cite         No.1         Cffice*         Number*         KindCode*         Name of Patiente or Applicant of Cited Document           EP         0827742         A1         Vrie Universitie Brussel           WO         9855499         A1         The University of Outerstand & The Queenstand & The Queenstand Study of Medical Research           WO         01/38322         A1         Methylgene, Inc.	Cite   Num of Patientee or   Name of Patientee or   Applicant of Cited Document   Patientee or   Patientee or   Applicant of Cited Document   Patientee or   Patientee or	Citics   Number   Sind-Code   Number   Sind-Code   Number   Citics   Number   Sind-Code   Number   Citics   Number   Sind-Code   Number   Citics   Number   Sind-Code   Number   Citics   Numb

Examiner Signature	/Kamal Saeed/	Date Considered	02/16/2009	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to epplicant.

I Unique citation designation number. See attacted Kinds of U.S. Platent Documents. Extra Office that issued this document, by the two-intercode WIPPO Standard ST.3, if or largenera planet occuments, be indication on the year of the inition of the Emparty must proceed the seation number of the patient document, s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, a Application is to place a check mank heroe if English Regionage Translation is attached.

Burden New Statement: This form is estimated to take 20 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be send to the Oxide Information Office, U.S. Pleast and Tradamark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS,SEND TO: Commissionar for Petents, P.O. Box 1450, Alexandria, Va 2313-1450

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OM9 0651-0031
U.S. Petant and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 2of 2

collection of information unless it displays	e valid OMB control number,
Application Number	10/507159
Filing Date	03/11/2003
First Named Inventor	Kristof Van Emelen
Group Art Unit	1621
Examiner Name	
Attorney Docket Number	PRD-2010 USPCT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²
/K.S./		Bunin, Barry A., The Combinatorial Index, 1998, Academic Press, San Diego, California.	
/KS/		Finney, D.J., Probit Analysis, Second Edition, Chapter 10, Graded Responses, 1952, University Press	
/K.S./		Finnin et al., "Structures of a Histone Deacetylase Homologue Bound to the TSA and SAHA Inhibitors.", Letters To Nature, September 1999, pages 188-193, Vol. 401.	
/K.S./		Gorrod et al., "The Metabolism of N-Ethyl-N-methylaniline by Rabbit Liver Microsomes: The Measurement of Metabolites by Gas-Liquid Chromatography.", Xanobiolica, 1975, pages 453-463, Vol. 5., No. 8.	
/K.S./		Marks et al., "Histone Deacetylases And Cancer: Causes and Therapies.", Nature, December 2001, pages 194-202, Vol. 1.	
/K.S./		Mosmann, Tim., "Rapid Colorimatric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays.", Journal of Immunological Methods, 1983, pages 55-63, Vol. 65.	
/K.S./		Pan, et al., "Soluble Polymer-Supported Synthesis of Arylpiperazines.", <u>Tetrahedron Letters</u> , 1998, pages 9505-9508, Vol. 39.	
/K.S./		The Combinatorial Chemistry Catalog, March 1999, Novabiochem.	
-			

Examiner Signature	/Kamal Saeed/	Date Considered	02/16/2009	

<sup>\*</sup>EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Drew line through citation it not in conformance and not considered, include copy of this form with next communication to applicant.

Burdsen New Stefament: This form is estimated to take 2.0 hours to complete. Three will vary depending upon the needs of the individual case, Any comments on the mount of time you as inequired to complete his form should be sent to the Chief Information Officer, U. S. Patent and Trademan Office, Washington, D.C 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO, Commissioner for Patents, P.O. Box 1450, Alexandrie, VA

22313-1450.

s Unique citation designation number, 2 Applicant is to place e check merk here if English lenguage Translation is attached,



## SUBMISSION UNDER MPEP 609 D

Application Number 10/507159
Filing Date 03/11/2003
First Named Inventor Kristol Van Emelen
Group Art Unit 1621 .
Examiner Name Attorney Docket Number PRD-2010 USPCT

Page 1 of 1

Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Numi		Kir	Pages, Columns, Lines, where relevant passages of relevant figures appear		
	No.		Num	XII	(II	known)	relevant ligure	s appear
	<u> </u>							
	<u> </u>							
	<del>-</del>	FOREIG	N PATENT	DOCUME	NTS	<u> </u>		
				atent Docum		Pages,	Columns, Lines,	
xaminer	Cite	Name of Patentee or				where relevant passages or relevant figures		To
nitials	No.1	Applicant of Cited Document	Office <sup>3</sup>	Number <sup>4</sup>	KindCode <sup>5</sup>		appear	<u>'</u>
-					T .			
				i —				
				<del> </del>				
	├			<del>                                     </del>				<del>  -</del>
	-			-	+			
		OTHER PRIOR ART - N	ON DATEN	LIVEDAY	DE DOCUME	170		
	T	Include name of the author (in C	APITOL LE	TTERS), t	itle of the arti	cle (when	appropriate),	Π.
Examiner s nitials*	Cite No.1	title of the item (book, magazine volume-issue number(s	e, journal, s s), publishe	erial, symp r, city and/o	osium, catalo or country wh	g, etc.), c ere publi:	late, page(s), shed	T <sup>2</sup>
/K.S./		International Search Report, Internal International Search Report May 22, 20	003	ation Numb	er PCT/EP03/	02517, Da	ite of Mailing of	
	$\vdash$							
	_							
								⊢-
								·
xaminer		/Kamal Saeed/		Date Consider	ad	02/16/	2009	

U.S. PATENT DOCUMENTS

U.S. Patent Document